Gene · 6241
Papers4,414
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
361 to 380 of 4,414
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| N6-methyladenosine modification of OIP5-AS1 promotes glycolysis, tumorigenesis, and metastasis of gastric cancer by inhibiting Trim21-mediated hnRNPA1 ubiquitination and degradation. | Gastric Cancer | 2024 | 37897508 | PubTator, text mining | PubMed |
| The pathogenic mechanism of TAR DNA-binding protein 43 (TDP-43) in amyotrophic lateral sclerosis. | Neural Regen Res | 2024 | 37843214 | PubTator, text mining | PubMed |
| Long-term prognostic value of the GenesWell BCT score in Asian women with hormone receptor-positive/HER2-negative early breast cancer. | Breast Cancer | 2024 | 37812303 | PubTator, text mining | PubMed |
| IGF2BPs as novel m6A readers: Diverse roles in regulating cancer cell biological functions, hypoxia adaptation, metabolism, and immunosuppressive tumor microenvironment. | Genes Dis | 2024 | 37692485 | PubTator, text mining | PubMed |
| A Four-Gene Panel for the Prediction of Prognosis and Immune Cell Enrichment in Gliomas. | Mol Biotechnol | 2024 | 37644261 | PubTator, text mining | PubMed |
| Ribonucleotide reductase M2 (RRM2): Regulation, function and targeting strategy in human cancer. | Genes Dis | 2024 | 37588202 | PubTator, text mining | PubMed |
| Novel Insights on Ferroptosis Modulation as Potential Strategy for Cancer Treatment: When Nature Kills. | Antioxid Redox Signal | 2024 | 37132605 | PubTator, text mining | PubMed |
| Impact of ferroptosis-related risk genes on macrophage M1/M2 polarization and prognosis in glioblastoma. | Front Cell Neurosci | 2023 | 38283752 | PubTator, text mining | PubMed |
| The Repurposing of Cellular Proteins during Enterovirus A71 Infection. | Viruses | 2023 | 38257775 | PubTator, text mining | PubMed |
| Personalization of Therapy in High-Grade Serous Tubo-Ovarian Cancer-The Possibility or the Necessity? | J Pers Med | 2023 | 38248751 | PubTator, text mining | PubMed |
| Prediction of Chemoresistance-How Preclinical Data Could Help to Modify Therapeutic Strategy in High-Grade Serous Ovarian Cancer. | Curr Oncol | 2023 | 38248100 | PubTator, text mining | PubMed |
| Simple models to understand complex disease: 10 years of progress from Caenorhabditis elegans models of amyotrophic lateral sclerosis and frontotemporal lobar degeneration. | Front Neurosci | 2023 | 38239833 | PubTator, text mining | PubMed |
| Identification of a Musashi2 translocation as a novel oncogene in myeloid leukemia. | bioRxiv | 2023 | 38234720 | PubTator, text mining | PubMed |
| Harnessing ADAR-Mediated Site-Specific RNA Editing in Immune-Related Disease: Prediction and Therapeutic Implications. | Int J Mol Sci | 2023 | 38203521 | PubTator, text mining | PubMed |
| RNA-Seq Analysis of Trans-Differentiated ARPE-19 Cells Transduced by AAV9-AIPL1 Vectors. | Int J Mol Sci | 2023 | 38203368 | PubTator, text mining | PubMed |
| miRNA-378 Is Downregulated by XBP1 and Inhibits Growth and Migration of Luminal Breast Cancer Cells. | Int J Mol Sci | 2023 | 38203358 | PubTator, text mining | PubMed |
| Biomarkers in Cancer Detection, Diagnosis, and Prognosis. | Sensors (Basel) | 2023 | 38202898 | PubTator, text mining | PubMed |
| A missense mutation in the suc22 gene encoding the small subunit of ribonucleotide reductase significantly sensitizes fission yeast to chronic treatment with hydroxyurea. | MicroPubl Biol | 2023 | 38188419 | PubTator, text mining | PubMed |
| Multiomics insights on the onset, progression, and metastatic evolution of breast cancer. | Front Oncol | 2023 | 38169859 | PubTator, text mining | PubMed |
| Canonical IRE1 function needed to sustain vigorous natural killer cell proliferation during viral infection. | iScience | 2023 | 38162021 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6241/papers?page=19